Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 10,000 shares at $28.03 ($280K) on 2025-01-02, disclosed to the SEC on 2025-01-06.
Scheduled sale ($280k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |